Roche Holding stock

ROP · SIX · CHF

Compare Roche Holding
CHF 406.20Change from previous close: −0.76%Absolute change: −CHF 3.10

Close · November 17, 2026

Price history

+42.06% over the period

1 year: from CHF 287.20 (November 17, 2025) to CHF 408.00 (November 17, 2026), +42.06%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026CHF 408.00
October 30, 2026CHF 403.40
September 30, 2026CHF 349.10
August 31, 2026CHF 352.80
July 31, 2026CHF 353.60
June 30, 2026CHF 332.80
May 29, 2026CHF 329.30
April 30, 2026CHF 318.40
March 31, 2026CHF 314.70
February 27, 2026CHF 367.00
January 30, 2026CHF 350.70
December 30, 2025CHF 328.20
November 28, 2025CHF 307.40
November 17, 2025CHF 287.20

At a glance

  • The company

    Pharmaceutical and diagnostics company offering medicines for multiple therapeutic areas and in vitro tests for disease diagnosis

  • Latest results

    Quarter to September 30, 2026

TickerLandia's take on Roche Holding

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 283.60
52-wk highCHF 409.50

−0.81% from the 52-week high

Analysts · 22 analysts

Average targetCHF 396.41−2.41% vs. price

Buy 11 · Hold 10 · Sell 1 · Buy

TickerLandia Fingerprint: Roche Holding

Compared with similar companies: very low growth and very strong momentum.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Roche Holding is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Roche Holding's P/E today is 25.4, above the median of its last 10 fiscal years (20.3; between 17.1 and 24.8 from 2016 to 2025). Roche Holding's P/E (trailing 12 months): 26.7, +24% against the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Roche Holding's metrics compared with similar companies
MetricRoche HoldingPosition in the groupBand
P/E (trailing 12 months)26.7High
Forward P/E18.5High
Operating margin33.1%Middle
ROE38.1%High
Debt/equity0.91Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Roche Holding. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

CHF 31.45B

Latest quarter · Q2 2026

Net income

CHF 6.87B

Latest quarter · Q2 2026

Quarterly net margin

21.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 325.56B
P/E
26.7
EPS
CHF 15.33
Volume
131.29K
Daily trading
€453.78M
Dividend yield
2.41%
Last ex-dividend on March 12, 2026

How Roche Holding is changing

All results
  • Revenue grew 1.0% a year on average over the last 5 years

  • Operating margin rose from 31.3% to 33.1%

  • Profits turn into cash: free cash flow equal to 135% of net income

Returns

Roche Holding returns with dividends

CHF 1,000 invested in Roche Holding 5 years ago, on November 17, 2021, would be worth CHF 1,297 today with dividends reinvested: +29.70% in total, +5.34% per year. On price alone it would be CHF 1,100 (+10.03%).

PeriodRoche HoldingSMICHF 1,000 becomes
1 month+7.34%+4.53%CHF 1,073
6 months+25.84%+13.61%CHF 1,258
Year to date+24.31%+13.20%CHF 1,243
1 year+46.44%+19.22%CHF 1,464
3 years+90.39%+39.88%CHF 1,904
5 years+29.70%+19.20%CHF 1,297
10 years+142.59%+88.57%CHF 2,426

Over the last 6 months it has done better than 39% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Roche Holding: technical analysis

Roche Holding is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.8% below its all-time closing high (CHF 409.30, November 16, 2026).

Trend
Upward
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
+17.05%

Support and resistance

Price areas where Roche Holding has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 406.20
  3. SupportCHF 375.10−7.66%3 touches, last on August 26, 2026
  4. SupportCHF 368.73−9.22%3 touches, last on September 23, 2026
  5. SupportCHF 348.75−14.14%2 touches, last on February 11, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
1.16
Volatility (60 sessions, annualised)
22.0%
Largest fall in the last year
−19.55%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Roche Holding: seasonality

Average monthly price change over 37 years

+1.6%Jan+0.2%Feb−0.5%Mar+0.8%Apr+2.3%May−0.2%Jun+1.7%Jul−0.7%Aug−0.3%Sep+1.8%Oct+2.5%Nov+1.5%Dec

Over the last 37 years, the strongest month for Roche Holding has been November: +2.47% on average, positive in 27 years out of 36. The weakest has been August: −0.73% on average, positive in 17 years out of 37.

Show chart data
MonthAverageMedianPositive years
January+1.56%+0.45%23 of 36
February+0.17%+0.11%19 of 37
March−0.49%−0.25%16 of 37
April+0.82%+0.04%19 of 37
May+2.29%+2.44%24 of 37
June−0.20%−1.31%16 of 37
July+1.72%+0.64%22 of 37
August−0.73%−0.12%17 of 37
September−0.33%−0.17%17 of 37
October+1.79%+2.19%24 of 37
November+2.47%+2.30%27 of 36
December+1.48%+0.90%21 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Roche Holding and its competitors

Founded in 1896 and based in Basel, Switzerland, the group develops prescription medicines and runs a diagnostics business, selling its products across Europe, North and Latin America, Asia, Africa and Australia. Its drug portfolio covers oncology, immunology, neurology, ophthalmology and transplant care, while its laboratory arm offers in vitro tests for conditions such as cancer, diabetes and hepatitis, together with diagnostic instruments and digital health tools. The company also collaborates with Excalipoint Therapeutics to evaluate EXP011 in solid tumours that express DLL3.

Headquarters
Basel, Switzerland
Employees
103,249
Founded
1896
Chief executive
Thomas Schinecker
Roche Holding and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Roche HoldingROP$387.48B33.1%26.7+25.84%
NovartisNOVN$305.16B34.0%32.6+14.23%
AstraZenecaAZN$287.12B25.8%26.6+1.25%
Novo NordiskNOVO.B$184.87B50.8%11.2−7.92%
SanofiSAN$116.52B22.3%25.5+17.04%
GSKGSK$102.04B30.5%18.0+0.35%

Same industry or related industries, similar size. Compare Roche Holding with its competitors · Full profile